ESKLEROSI ANITZA
![Foto de ESKLEROSI ANITZA](/img/grupo.png)
![Foto de University of Melbourne](/img/noimage_org.png)
University of Melbourne
Melbourne, AustraliaUniversity of Melbourne-ko ikertzaileekin lankidetzan egindako argitalpenak (13)
2024
-
Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategies
Journal of neurology, Vol. 271, Núm. 1, pp. 472-485
-
Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches
Journal of Extracellular Vesicles, Vol. 13, Núm. 2
2023
-
Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis
JAMA Neurology, Vol. 80, Núm. 7, pp. 702-713
-
Comparative effectiveness in multiple sclerosis: A methodological comparison
Multiple Sclerosis Journal, Vol. 29, Núm. 3, pp. 326-332
-
Disability accrual in primary and secondary progressive multiple sclerosis
Journal of Neurology, Neurosurgery and Psychiatry, Vol. 94, Núm. 9, pp. 707-717
-
Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial
Journal of neurology, neurosurgery, and psychiatry, Vol. 94, Núm. 12, pp. 1004-1011
-
The risk of secondary progressive multiple sclerosis is geographically determined but modifiable
Brain : a journal of neurology, Vol. 146, Núm. 11, pp. 4633-4644
-
Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis
European Journal of Neurology, Vol. 30, Núm. 4, pp. 1014-1024
2022
-
Confirmed disability progression as a marker of permanent disability in multiple sclerosis
European Journal of Neurology, Vol. 29, Núm. 8, pp. 2321-2334
-
Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis
Neurology, Vol. 99, Núm. 17, pp. E1926-E1944
-
Heterogeneity on long-term disability trajectories in patients with secondary progressive MS: a latent class analysis from Big MS Data network
Journal of Neurology, Neurosurgery and Psychiatry, Vol. 94, Núm. 1, pp. 23-30
2021
-
Determinants of therapeutic lag in multiple sclerosis
Multiple Sclerosis Journal, Vol. 27, Núm. 12, pp. 1838-1851
-
Natalizumab, Fingolimod, and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis
Neurology, Vol. 96, Núm. 24, pp. E2989-E3002